Bulletin
Investor Alert

New York Markets Open in:

press release

March 17, 2022, 8:40 a.m. EDT

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

LAUSANNE, Switzerland, (BUSINESS WIRE) -- ADC Therapeutics SA /zigman2/quotes/214411413/composite ADCT +5.60% , a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2021, has been filed with the U.S. Securities and Exchange Commission (the “SEC”).

ADC Therapeutics’ Annual Report on Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor section of the Company’s website at ir.adctherapeutics.com . In addition, shareholders may request a hard copy of the Company’s audited financial statements, or its complete Annual Report on Form 20-F which include the audited financial statements, free of charge, by contacting IR@adctherapeutics.com.

About ADC Therapeutics

ADC Therapeutics /zigman2/quotes/214411413/composite ADCT +5.60% is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005065/en/

SOURCE: ADC Therapeutics SA

Investors Eugenia Litz
ADC Therapeutics
Eugenia.Litz@adctherapeutics.com
+44 7879 627205 Amanda Hamilton
ADC Therapeutics
amanda.hamilton@adctherapeutics.com
+1 917-288-7023 EU Media
Alexandre Müller
Dynamics Group
amu@dynamicsgroup.ch
+41 (0) 43 268 3231 USA Media
Mary Ann Ondish
ADC Therapeutics
maryann.ondish@adctherapeutics.com
+1 914-552-4625

COMTEX_404298283/2456/2022-03-17T08:40:29

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 8.30
+0.44 +5.60%
Volume: 226,995
Aug. 5, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$587.06 million
Rev. per Employee
$257,740
loading...
/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 8.30
+0.44 +5.60%
Volume: 226,995
Aug. 5, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$587.06 million
Rev. per Employee
$257,740
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.